- max: .... thanks for information....
- jesse: .... thanks!!...
- Jay: .... tnx for info!!...
- 毛冬蕾的空间 » Blog Archive » 没有忘记DIA第六届年会: [...] http://www.maodl.com/?p=2576 [...]
- 毛冬蕾的空间 » Blog Archive » 没有忘记DIA第六届年会: [...] http://www.maodl.com/?p=1558 [...]
- 毛冬蕾的空间 » Blog Archive » 没有忘记DIA第六届年会: [...] http://www.maodl.com/?p=157 [...]
- Donglei: Thanks Brian!Look forward to reading your article too.
The balance of interests of domestic industry and foreign industry must be handled properly, opening of clinical trial must lead to the influx of drug made by foreign manufacturers, and a series of impacts on occupation of clinical resources, market sharing, public’s access to reference listed drug (RLD), pricing differences of patent drug and generic drug, and so on, which should be considered and responded stably by the drug regulator.
—–Zhang Wei, Director, Drug Registration Department, State Food and Drug Administration (SFDA)